Skip to main content
Epocrates Online
Contact us
Explore features
Reach clinicians
Buy now
By
vgreene
, 5 June, 2019
Subsequent testing (if ER/PR/HER2 status already known)
By
vgreene
, 5 June, 2019
HER2 (for invasive breast CA pts)
By
vgreene
, 5 June, 2019
Initial testing:
By
vgreene
, 5 June, 2019
tumor progesterone receptor (PR) status1-4
By
vgreene
, 5 June, 2019
tumor estrogen receptor (ER) status: 1-4 AND
By
vgreene
, 5 June, 2019
For node-negative, ER/PR+, HER2 pts, consider 1 of the following:
By
vgreene
, 5 June, 2019
BCI
By
vgreene
, 5 June, 2019
EndoPredict
By
vgreene
, 5 June, 2019
MammaPrint
By
vgreene
, 5 June, 2019
Oncotype DX
Pagination
First page
Previous page
…
Page
2369
Page
2370
Page
2371
Page
2372
Current page
2373
Page
2374
Page
2375
Page
2376
Page
2377
…
Next page
Last page
About Us
Company Overview
Media Relations
Contact
Editorial Policy
Editorial Process
Third-Party Sponsorship Policy
athenahealth
Products
Core Products
Mobile CME
Product Licenses
Business Solutions
Pharma
Market Research
Institutions
Support
Support Center
Install
My Account
Stay Connected
Facebook
Twitter
YouTube